Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

S*BIO Restructures Agreement With Onyx for JAK2 Inhibitor Program

May 4, 2011 By Bio-Medicine.Org

SINGAPORE, May 4, 2011 /PRNewswire/ — S*BIO Pte Ltd today
announced the restructuring of its collaboration and option
agreement with Onyx Pharmaceuticals, which was entered into in
January 2009. As a result, S*BIO has regained North American and
European rights to its novel JAK2 inhibitors, SB1518 and SB1578,
from Onyx.  Following a successful and productive partnership
with Onyx, S*BIO will now be in a position to drive the development
of its lead JAK2 program independently.

Recent data from Phase 2 clinical trials of SB1518 indicated
promising clinical efficacy and good tolerability for the treatment
of myelofibrosis (MF), an orphan indication with high unmet medical
need.  SB1518 has also demonstrated clinical benefits in
patients with relapsed/refractory lymphoma. S*BIO plans to advance
SB1518 and SB1578 expeditiously through clinical development, with
pivotal trials for SB1518 anticipated to begin later this year.

“Consolidating North American and European rights for SB1518 and
SB1578 represents a unique opportunity for S*BIO to steer the
global development of these two promising products,” said Dr.
Jan-Anders Karlsson, CEO of S*BIO. “Our strong relationship with
Onyx has led to the successful clinical advancement of both SB1518
and SB1578.  SB1518 has now reached a critical inflection
point where its future success in a highly competitive field
depends on an aggressive and focused development plan. As an
existing shareholder, Onyx’s interests remain aligned with S*BIO’s
objective to maximize the value of the JAK2 program and to share in
the upside potential of SB1518 and other S*BIO assets.”

About S*BIO Pte LtdS*BIO is a privately-held biotech company
focused on the research and clinical development of novel targeted
small molecule drugs for the treatment of cancer with leading
programs around kinases and histone deacetylases (HDAC). SB1518,
S*BIO’s potent and orally-active JAK2 inhibitor, entered the clinic
in 2008

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech